Previously, we demonstrated that Bintrafusp/SX therapy can significantly reduce tumor infiltration with suppressive granulocytic myeloid-derived suppressor cells (G-MDSC), defined as CD11b+F4/80−Ly6CloLy6G+, an effect attributed to the ability of SX-682 to block the CXCR1/2-mediated migration of G-MDSC into the tumor. This evidence concerns the gene CXCR1 and neoplasm.